###begin article-title 0
###xml 52 57 <span type="species:ncbi:9606">Human</span>
Mutation of von Hippel-Lindau Tumour Suppressor and Human Cardiopulmonary Physiology
###end article-title 0
###begin p 1
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: PHM, CWP, and PJR are scientific co-founders of ReOx ( ). 
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 796 801 <span type="species:ncbi:9606">human</span>
The von Hippel-Lindau tumour suppressor protein-hypoxia-inducible factor (VHL-HIF) pathway has attracted widespread medical interest as a transcriptional system controlling cellular responses to hypoxia, yet insights into its role in systemic human physiology remain limited. Chuvash polycythaemia has recently been defined as a new form of VHL-associated disease, distinct from the classical VHL-associated inherited cancer syndrome, in which germline homozygosity for a hypomorphic VHL allele causes a generalised abnormality in VHL-HIF signalling. Affected individuals thus provide a unique opportunity to explore the integrative physiology of this signalling pathway. This study investigated patients with Chuvash polycythaemia in order to analyse the role of the VHL-HIF pathway in systemic human cardiopulmonary physiology.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 7 19 <span type="species:ncbi:9606">participants</span>
###xml 118 130 <span type="species:ncbi:9606">Participants</span>
Twelve participants, three with Chuvash polycythaemia and nine controls, were studied at baseline and during hypoxia. Participants breathed through a mouthpiece, and pulmonary ventilation was measured while pulmonary vascular tone was assessed echocardiographically. Individuals with Chuvash polycythaemia were found to have striking abnormalities in respiratory and pulmonary vascular regulation. Basal ventilation and pulmonary vascular tone were elevated, and ventilatory, pulmonary vasoconstrictive, and heart rate responses to acute hypoxia were greatly increased.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 45 53 <span type="species:ncbi:9606">patients</span>
The features observed in this small group of patients with Chuvash polycythaemia are highly characteristic of those associated with acclimatisation to the hypoxia of high altitude. More generally, the phenotype associated with Chuvash polycythaemia demonstrates that VHL plays a major role in the underlying calibration and homeostasis of the respiratory and cardiovascular systems, most likely through its central role in the regulation of HIF.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cells (like those of other multicellular animals) use oxygen to provide the energy needed for daily life. Having not enough oxygen is a problem, but having too much is also dangerous because it damages proteins, DNA, and other large molecules that keep cells functioning. Consequently, the physiological systems-including the heart, lungs, and circulation-work together to balance oxygen supply and demand throughout the body. When oxygen is limiting (a condition called hypoxia), as happens at high altitudes, the cellular oxygen supply is maintained by increasing the heart rate, increasing the speed and depth of breathing (hyperventilation), constricting the blood vessels in the lung (pulmonary vasoconstriction), and increasing the number of oxygen-carrying cells in the blood. All these physiological changes increase the amount of oxygen that can be absorbed from the air, but how they are regulated is poorly understood. By contrast, researchers know quite a bit about how individual cells respond to hypoxia. When oxygen is limited, a protein called hypoxia-inducible factor (or HIF) activates a number of target proteins that help the cell get enough oxygen (for example, proteins that stimulate the growth of new blood vessels). When there is plenty of oxygen, another protein, called von Hippel-Lindau tumor suppressor (abbreviated VHL), rapidly destroys HIF. Recently, researchers discovered that a genetic condition called Chuvash polycythaemia, characterised by the overproduction of red blood cells, is caused by a specific defect in VHL that reduces its ability to destroy HIF. As a result, the expression of certain HIF target proteins is increased even when oxygen levels are normal.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
Chuvash polycythaemia is very rare, and so far little is known about how this genetic abnormality affects the physiology and long-term health of patients. By studying heart and lung function in patients with Chuvash polycythaemia, the researchers involved in this study hoped to discover more about the health consequences of the condition and to find out whether the VHL-HIF system controls systemic responses to hypoxia as well as cellular responses.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 252 258 <span type="species:ncbi:9606">people</span>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
The researchers recruited and studied three patients with Chuvash polycythaemia, and, as controls for the comparison, several normal individuals and patients with an unrelated form of polycythaemia. They then measured how the lungs and hearts of these people reacted to mild hypoxia (similar to that experienced on commercial air flights) and moderate hypoxia (equiv alent to being on the top of an Alpine peak). They found that patients with Chuvash polycythaemia naturally breathe slightly quicker and deeper than normal individuals, and that their breathing rate increased dramatically and abnormally when oxygen was reduced. They also found that at normal oxygen levels the pulmonary blood vessels of these patients were more constricted than those of control individuals, and that they reacted more extremely to hypoxia. Similarly, the normal heart rate of the patients was slightly higher than that of the controls and increased much more in response to mild hypoxia.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 160 166 <span type="species:ncbi:9606">people</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 581 587 <span type="species:ncbi:9606">people</span>
The physiological differences measured by the researchers between Chuvash polycythaemia patients and control individuals are similar to the adaptations seen in people traveling to high altitudes where oxygen is limited. Thus, the VHL-HIF proteins may regulate the response to different oxygen concentrations both in individual cells and at the systemic level, although more physiological studies are needed to confirm this. Because the pulmonary blood vessels of patients with Chuvash polycythaemia are always abnormally constricted, and even more so when oxygen is limited, these people should avoid living at high altitude and should minimise air travel, suggest the researchers. The increased blood pressure in their lungs (pulmonary hypertension) could conceivably cause heart failure under such circumstances. Finally, this study has implications for the development of drugs directed at the VHL-HIF system. Agents are currently being designed to promote the development of new blood vessels after strokes or heart attacks by preventing the destruction of HIF, but based on the findings here such agents might have undesirable physiological affects. Conversely, HIF inhibitors (which act as anti-cancer reagents by increasing hypoxia in the centre of tumors and so inhibiting their growth) might be useful in the treatment of pulmonary hypertension.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at . 
###end p 18
###begin p 19
###xml 34 37 <span type="species:ncbi:9606">Man</span>
* Online Mendelian Inheritance in Man page on 
###end p 19
###begin p 20
* Information from the VHL Family Alliance on , including information on 
###end p 20
###begin p 21
* Wikipedia page on  and  (note: Wikipedia is a free online encyclopaedia that anyone can edit) 
###end p 21
###begin p 22
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Physiological study of patients with Chuvash polycythemia (caused by mutation of VHL) reveals characteristics similar to those associated with acclimatization to the hypoxia of high altitude.
###end p 22
###begin title 23
Introduction
###end title 23
###begin p 24
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b001">1</xref>
###xml 753 754 753 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b002">2</xref>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b003">3</xref>
###xml 977 978 969 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b004">4</xref>
###xml 980 981 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b005">5</xref>
###xml 1106 1107 1090 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b002">2</xref>
###xml 1109 1110 1093 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b003">3</xref>
###xml 1466 1467 1446 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b006">6</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 1528 1533 <span type="species:ncbi:9606">human</span>
Hypoxia is universally experienced at high altitudes and is a detrimental feature of many medical conditions. The human response to acute hypoxia includes hyperventilation, pulmonary vasoconstriction, systemic peripheral vasodilation, and tachycardia. Our understanding of how these systemic responses are evoked and regulated remains limited. However, it is now known that intracellular responses to hypoxia are coordinated by the hypoxia-inducible factor (HIF) family of transcription factors, which directly or indirectly regulate the expression of several hundred genes in any given cell type [ 1]. The von Hippel-Lindau tumour suppressor protein (VHL) is an essential component in the degradation pathway through which HIF is primarily regulated [ 2, 3]. The HIF-alpha subunit is synthesised continuously but is rapidly destroyed in the presence of oxygen. Oxygen-dependent prolyl hydroxylases hydroxylate specific residues in HIF-alpha, increasing its affinity for VHL [ 4, 5]. The binding of VHL to hydroxylated HIF-alpha then targets HIF-alpha for destruction by the ubiquitin-proteasome pathway [ 2, 3]. Under hypoxic conditions, the hydroxylation of HIF-alpha is inhibited, proteasomal degradation is slowed, and thus there is rapid accumulation of HIF with subsequent up-regulation of hypoxia-responsive genes. Manipulation of the VHL-HIF pathway is currently under intense investigation as a treatment for cancer and ischaemic/hypoxic vascular disease [ 6]. However, the role of the VHL-HIF pathway in systems-level human physiology remains largely unknown. 
###end p 24
###begin p 25
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b007">7</xref>
In the classical VHL-associated inherited cancer syndrome, affected individuals are heterozygous for a germline VHL mutation that predisposes to specific types of tumour [ 7]. Known clinical manifestations are confined to tumours and discrete benign lesions that arise following somatic inactivation of the second allele. Disturbance of hypoxia signalling is limited to tumour cells, and studies of these effects have been confined to the phenotype of associated renal cell carcinoma and to lesions that develop in rodent models of VHL inactivation. Such analyses essentially examine the effects of complete dysregulation of the VHL-HIF system at the cellular level. 
###end p 25
###begin p 26
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">598C&gt;T</italic>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b008">8</xref>
###xml 509 529 501 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">erythropoietin (EPO)</italic>
###xml 532 533 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b008">8</xref>
###xml 311 317 <span type="species:ncbi:9606">humans</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
Chuvash polycythaemia (CP) is a rare autosomal recessive disorder caused by an entirely distinct disease mechanism. Affected individuals are homozygous for a specific 598C>T mutation in VHL [ 8] that impairs but does not ablate the regulation of HIF-potentially allowing insights into its systemic functions in humans. The VHL mutation diminishes VHL's binding affinity for hydroxylated HIF-alpha, thereby partially inhibiting HIF-alpha degradation and pathologically up-regulating HIF target genes including erythropoietin (EPO) [ 8]. CP is characterised by congenital erythrocytosis, but has yet to be extensively phenotyped. Through experiments conducted with CP patients, this study aimed to investigate the potential role of the VHL pathway in cardiopulmonary physiology. It has demonstrated profound abnormalities in ventilatory and pulmonary vascular control in affected individuals. 
###end p 26
###begin title 27
Methods
###end title 27
###begin title 28
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 28
###begin p 29
###xml 58 65 58 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030290-t001">Table 1</xref>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b009">9</xref>
###xml 1351 1358 1345 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030290-t001">Table 1</xref>
###xml 32 44 <span type="species:ncbi:9606">participants</span>
###xml 67 75 <span type="species:ncbi:9606">Patients</span>
###xml 198 205 <span type="species:ncbi:9606">patient</span>
###xml 355 362 <span type="species:ncbi:9606">patient</span>
###xml 567 574 <span type="species:ncbi:9606">patient</span>
###xml 770 777 <span type="species:ncbi:9606">patient</span>
###xml 949 957 <span type="species:ncbi:9606">patients</span>
###xml 1010 1022 <span type="species:ncbi:9606">participants</span>
###xml 1028 1031 <span type="species:ncbi:9606">men</span>
###xml 1090 1095 <span type="species:ncbi:9606">woman</span>
###xml 1184 1192 <span type="species:ncbi:9606">patients</span>
###xml 1294 1302 <span type="species:ncbi:9606">patients</span>
###xml 1335 1342 <span type="species:ncbi:9606">patient</span>
###xml 1421 1432 <span type="species:ncbi:9606">participant</span>
###xml 1612 1624 <span type="species:ncbi:9606">participants</span>
###xml 1779 1790 <span type="species:ncbi:9606">participant</span>
Physical characteristics of the participants are given in Table 1. Patients with CP were identified from a previous study [ 9] and recruited through their respective consultant haematologists. Each patient was homozygous for the classic Chuvash mutation and had been treated with long-term venesection to maintain a normal haemoglobin and haematocrit. No patient had been venesected within several weeks of the experiment. They had no other medical disorders, had no history of complications, and were asymptomatic except for occasional headaches. The size of the CP patient group was limited by the rarity of the condition in the United Kingdom. The normal control group comprised six age- and sex-matched healthy volunteers who were recruited by advertisement. The CP patient group (age 22.3 +/- 5 y, mean +/- SD) and the normal control group (24.2 +/- 5 y) did not differ significantly in age, height, weight, or body mass index. A further three patients were recruited as sex-matched polycythaemia control participants: two men diagnosed with acquired idiopathic erythrocytosis and one woman with polycythaemia vera. No mutations were detected on sequencing the VHL gene in these patients. Each was otherwise in good health and had been chronically venesected to a normal hematocrit. These patients were somewhat older than the CP patient group ( Table 1) but were otherwise similar. The female polycythaemia control participant was taking daily aspirin and citalopram, and one male polycythaemia control was taking daily atenolol, aspirin, and simvastatin for cardiovascular disease prophylaxis. Otherwise, participants were taking no medications, vitamin supplements, or caffeine. The study had been approved by the Oxfordshire Clinical Research Ethics Committee, and each participant provided written informed consent. 
###end p 29
###begin title 30
Studies of HIF-Regulated Gene Expression
###end title 30
###begin p 31
###xml 1326 1336 1314 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aldolase C</italic>
###xml 1341 1382 1329 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vascular endothelial growth factor (VEGF)</italic>
###xml 1525 1526 1510 1511 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1520 1541 1508 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946; <sub>2</sub>-microglobulin </italic>
###xml 2021 2023 2006 2008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b010">10</xref>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 425 431 <span type="species:ncbi:9913">bovine</span>
###xml 2130 2138 <span type="species:ncbi:9606">patients</span>
These studies were undertaken to confirm differences in HIF-regulated gene expression at the mRNA level in CP patients compared with normal controls. Mononuclear cells were isolated by centrifugation of venous blood over a density gradient medium (Ficoll-Paque Plus, Amersham Biosciences, Chalfont, United Kingdom). The mononuclear cells were resuspended in 40 ml of RPMI 1640 cell culture medium supplemented with 10% fetal bovine serum, L-glutamine, and penicillin/streptomycin antibiotics (Sigma-Aldrich, Gillingham, United Kingdom). The cells were placed in tissue culture dishes with a hydrophilic base (Vivascience, Hannover, Germany) at 37 degreesC for 30 min to allow for adherence of the monocytes to the base. The supernatant containing the lymphocytes was then removed and aliquotted into eight tissue culture dishes in which the base was both hydrophobic and gas permeable (Vivascience). Lymphocytes were incubated for 20 h at 37 degreesC in 5% carbon dioxide and at one of eight different oxygen tensions (20%, 10%, 5%, 2%, 1%, 0.5%, 0.2%, or 0.1%). The cells were then harvested and RNA was isolated using a column-based centrifugation extraction protocol (RNAqueous-4PCR; Ambion-Europe, Huntingdon, United Kingdom). RNA samples were reverse transcribed using random hexamer primers, and the HIF-regulated genes Aldolase C and vascular endothelial growth factor (VEGF) were quantified by real-time quantitative PCR using Taqman primers and probes (Applied Biosystems, Warrington, United Kingdom). The gene beta 2-microglobulin  was used as an internal experimental control and was quantified by the same method. A standard calibrator sample of cDNA was assayed for these three genes with each set of real-time quantitative PCR reactions. This sample was derived from the pooled RNA of two 20-h incubations of lymphocytes at 20% and 0.1% oxygen. Levels of gene expression relative to the calibrator sample were corrected for differences in the PCR efficiencies of the primers and probes used for each gene [ 10]. This entire procedure was repeated for blood samples drawn on three separate days from each of three CP patients and three age- and sex-matched normal controls. 
###end p 31
###begin title 32
Physiology Protocols
###end title 32
###begin p 33
###xml 216 219 216 219 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 221 222 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 219 222 219 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O <sub>2</sub></sub>
###xml 245 248 245 248 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 251 252 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 248 252 248 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO <sub>2</sub></sub>
###xml 642 645 642 645 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 647 648 647 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 645 648 645 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O <sub>2</sub></sub>
###xml 700 703 700 703 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 705 706 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 703 706 703 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O <sub>2</sub></sub>
###xml 894 897 894 897 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 899 900 899 900 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 897 900 897 900 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O <sub>2</sub></sub>
###xml 1096 1099 1096 1099 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 1102 1103 1102 1103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1099 1103 1099 1103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO <sub>2</sub></sub>
###xml 9 20 <span type="species:ncbi:9606">participant</span>
###xml 97 109 <span type="species:ncbi:9606">Participants</span>
###xml 324 335 <span type="species:ncbi:9606">participant</span>
###xml 476 488 <span type="species:ncbi:9606">participants</span>
###xml 1129 1140 <span type="species:ncbi:9606">participant</span>
For each participant, the experimental observations were made during the course of a single day. Participants reported to the laboratory at 8:30 A.M., where their air-breathing end-tidal partial pressure of oxygen ( PetO 2) and carbon dioxide ( PetCO 2) were measured, and venous and arterial blood samples were drawn. Each participant then undertook an identical series of four separate protocols, with 20 min separating each protocol. The first two protocols determined the participants' responses to very mild hypoxia, which approximated the level of hypoxia commonly experienced during commercial air travel. An initial 5 min of euoxia ( PetO 2 of 100 mm Hg) was followed by 10 min of hypoxia at PetO 2 of 70 mm Hg, which was then followed by a final 5 min of euoxia. The second two protocols followed an identical time course but determined responses to moderate hypoxia, using a stimulus PetO 2 of 50 mm Hg rather than 70 mm Hg. This was close to the level of hypoxia experienced during acute exposure to an altitude of 3,500 m. Isocapnia was maintained throughout all four protocols, with PetCO 2 maintained close to each participant's baseline value. 
###end p 33
###begin title 34
Experimental Technique
###end title 34
###begin p 35
###xml 210 211 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 207 211 207 211 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Po <sub>2</sub></sc>
###xml 339 340 339 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 340 335 340 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pco <sub>2</sub></sc>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b011">11</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b012">12</xref>
###xml 1219 1221 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b013">13</xref>
###xml 1223 1225 1223 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b020">20</xref>
###xml 1428 1431 1424 1427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 1561 1563 1557 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b021">21</xref>
###xml 1587 1590 1579 1582 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 1847 1849 1839 1841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b014">14</xref>
###xml 1851 1853 1843 1845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b015">15</xref>
###xml 2069 2072 2057 2060 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 395 406 <span type="species:ncbi:9606">participant</span>
Gas control during the four protocols was achieved using a technique known as dynamic end-tidal forcing, whereby a computer-controlled fast gas-mixing system allows the alveolar partial pressure of oxygen ( Po 2) to be manipulated rapidly and accurately while at the same time maintaining alveolar partial pressure of carbon dioxide ( Pco 2) constant [ 11]. Each protocol was conducted with the participant reclining in the left lateral position and breathing through a mouthpiece whilst wearing an occlusive nose clip. Ventilation was measured using a turbine volume-measuring device [ 12], and these data were averaged from the two protocols undertaken at each level of hypoxia. Respired gases were analysed continuously by mass spectrometry. These data were logged in real time to a personal computer that was at the same time controlling the end-tidal gas composition. A Hewlett-Packard (Palo Alto, California, United States) Sonos 5500 ultrasound machine with an S4 two-dimensional transducer (2-4 MHz) was used to perform continuous echocardiography. During the first protocol at each level of hypoxia, pulmonary vascular tone was assessed using a standard Doppler technique that has been extensively validated [ 13- 20]. In this technique, the maximum velocity of a regurgitant jet of blood through the tricuspid valve is measured during systole. The maximum systolic pressure gradient across the tricuspid valve (DeltaP max) is then calculated beat by beat from this velocity using Bernoulli's equation. Right atrial pressure is unaffected by hypoxia [ 21], so changes in DeltaP max reflect changes in systolic pulmonary artery pressure. During the second protocol at each level of hypoxia, cardiac output was determined beat by beat using Doppler echocardiography to measure the velocity of systolic blood flow through the aortic valve [ 14, 15]. Heart rate was monitored by electrocardiography, and blood pressure was measured each minute using an automated cuff. Breath-by-breath measurements of pulmonary ventilation and beat-by-beat measurements of DeltaP max, cardiac output, and heart rate were averaged over 1-min periods. 
###end p 35
###begin title 36
Statistical Analyses
###end title 36
###begin p 37
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 225 226 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Specific differences between CP patients and normal controls were assessed statistically using Student's unpaired t-test (Microsoft Excel; Microsoft, Seattle, Washington, United States) and were considered significant at the p < 0.05 level. Other general comparisons of the effects of hypoxia were performed using a univariate repeated measures ANOVA, using the Greenhouse-Geisser correction to derive the degrees of freedom (SPSS statistical package; SPSS, Chicago, Illinois, United States). 
###end p 37
###begin title 38
Results
###end title 38
###begin p 39
###xml 62 69 <span type="species:ncbi:9606">patient</span>
###xml 196 208 <span type="species:ncbi:9606">participants</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
The main results are presented as a comparison between the CP patient group and the age- and sex-matched normal healthy controls. The final section presents results from the polycythaemia control participants, as a comparison both with the normal controls and with the CP patients.
###end p 39
###begin title 40
Baseline Measurements
###end title 40
###begin p 41
###xml 70 77 70 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030290-t002">Table 2</xref>
###xml 92 95 92 95 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pco</sc>
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
Results obtained from venous and arterial blood analyses are shown in Table 2. The arterial Pco2 was on average 6 mm Hg lower in the CP patients than in the matched normal controls ( p < 0.05). All CP patients had been chronically treated with venesection, and had normal haemoglobin and haematocrit with concomitant iron deficiency. 
###end p 41
###begin title 42
Studies of Gene Expression
###end title 42
###begin p 43
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 127 135 127 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030290-g001">Figure 1</xref>
###xml 138 148 138 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aldolase C</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 408 418 408 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aldolase C</italic>
###xml 477 481 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 101 108 <span type="species:ncbi:9606">patient</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
Basal (non-hypoxic) expression of the HIF-regulated genes studied was significantly higher in the CP patient group ( p < 0.05; Figure 1). Aldolase C expression was 130% greater than in the controls, while VEGF expression was 90% greater. Both genes were induced by hypoxia, but at the most marked level of hypoxia, expression was no longer significantly greater in the CP patients. At this level of hypoxia, Aldolase C expression was only 34% greater than in the controls, and VEGF expression was only 37% greater. Thus, the effect of the VHL mutation was most striking under euoxic conditions, when the rate of hydroxylation of HIF-alpha is at its fastest. 
###end p 43
###begin title 44
Pulmonary Ventilatory Measurements
###end title 44
###begin p 45
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030290-g002">Figure 2</xref>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 765 766 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 142 149 <span type="species:ncbi:9606">patient</span>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 391 403 <span type="species:ncbi:9606">participants</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 581 588 <span type="species:ncbi:9606">patient</span>
###xml 749 756 <span type="species:ncbi:9606">patient</span>
Figure 2 illustrates pulmonary ventilation at baseline and in response to hypoxia. During euoxia, ventilation was sometimes greater in the CP patient group than in the normal control group. Exposure to mild hypoxia provoked a 2.8-fold greater increase in ventilation in CP patients than in normal controls ( p < 0.02), in whom there was very little change in ventilation. For normal control participants, although ventilation increased more with moderate than mild hypoxia, all protocols were well tolerated. In contrast, the CP patients tolerated moderate hypoxia poorly, and one patient withdrew from the moderate hypoxia protocol with nausea and severe dyspnea. The rise in ventilation produced by moderate hypoxia was 2.4-fold greater in the CP patient group ( p < 0.05). 
###end p 45
###begin title 46
Pulmonary Vascular Measurements
###end title 46
###begin p 47
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 174 182 174 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030290-g002">Figure 2</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b022">22</xref>
###xml 468 471 464 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 567 570 559 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 649 650 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 673 676 661 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 805 806 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 374 386 <span type="species:ncbi:9606">participants</span>
###xml 633 640 <span type="species:ncbi:9606">patient</span>
The CP patients displayed an abnormally high set point around which pulmonary arterial pressure was regulated, which was almost double that of the control group ( p < 0.005; Figure 2) and which, assuming a standard right atrial pressure of 5 mm Hg, exceeded the cut-off for pulmonary hypertension (pulmonary arterial pressure greater than 25 mm Hg) [ 22]. In normal control participants, as expected, exposure to mild hypoxia produced only a very small rise in DeltaP max, reflecting their minimal pulmonary vasoconstrictive response. However, the increase in DeltaP max provoked by the same stimulus was 10.7-fold greater in the CP patient group ( p < 0.01). Their DeltaP max response to moderate hypoxia was likewise extremely abnormal, and was 5.8-fold greater than that for the normal control group ( p < 0.001). 
###end p 47
###begin title 48
Systemic Vascular Measurements
###end title 48
###begin p 49
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 115 123 115 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030290-g003">Figure 3</xref>
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 90 102 <span type="species:ncbi:9606">participants</span>
###xml 208 215 <span type="species:ncbi:9606">patient</span>
There was a trend towards a higher baseline heart rate in CP patients than normal control participants ( p = 0.06; Figure 3), and upon transition to mild hypoxia, heart rate increased 3.2-fold more in the CP patient group ( p < 0.005); the corresponding difference was not statistically significant with moderate hypoxia (1.6-fold, p = 0.21). Changes in cardiac output followed a similar pattern to changes in heart rate but did not differ significantly between the two groups. 
###end p 49
###begin title 50
###xml 22 34 <span type="species:ncbi:9606">Participants</span>
Polycythaemia Control Participants
###end title 50
###begin p 51
###xml 147 154 147 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030290-t002">Table 2</xref>
###xml 250 253 250 253 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pco</sc>
###xml 253 254 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 26 38 <span type="species:ncbi:9606">participants</span>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 213 220 <span type="species:ncbi:9606">patient</span>
###xml 297 304 <span type="species:ncbi:9606">patient</span>
###xml 507 519 <span type="species:ncbi:9606">participants</span>
###xml 572 583 <span type="species:ncbi:9606">participant</span>
The polycythaemia control participants, like the CP patients, were iron-deficient with microcytic indices but normal haemoglobin and haematocrit ( Table 2). However, the polycythaemia control group, unlike the CP patient group, had a normal arterial Pco2 (significantly higher than that of the CP patient group, p < 0.01). Baseline pulmonary and systemic blood pressures were higher in the polycythaemia controls compared with the normal control group, but it should be noted that the polycythaemia control participants were older. The data from the polycythaemia control participant taking atenolol were excluded from the analyses of systemic vascular data. 
###end p 51
###begin p 52
###xml 40 43 36 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 152 161 148 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030290-g002">Figures 2</xref>
###xml 166 167 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030290-g003">3</xref>
###xml 182 190 178 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030290-g004">Figure 4</xref>
###xml 250 262 <span type="species:ncbi:9606">participants</span>
###xml 398 409 <span type="species:ncbi:9606">participant</span>
###xml 483 495 <span type="species:ncbi:9606">participants</span>
###xml 718 726 <span type="species:ncbi:9606">patients</span>
###xml 773 785 <span type="species:ncbi:9606">participants</span>
###xml 835 842 <span type="species:ncbi:9606">patient</span>
The mean responses (ventilation, DeltaP max, heart rate, blood pressure, and cardiac output) of the polycythaemia control group to hypoxia are shown in Figures 2 and 3. In addition, Figure 4 illustrates the sensitivities to hypoxia of the individual participants from all three experimental groups. These are expressed in terms of the number of (normal control group) standard deviations that each participant's response deviated from the mean response of the normal healthy control participants. The responses of the polycythaemia control group never differed significantly from those of the normal control group (repeated measures ANOVA). This demonstrates that the major alterations in physiology present in the CP patients were not present in the polycythaemia control participants. As a final check on the overall results, the CP patient group was compared with the pooled control groups using repeated measures ANOVA. In all cases this analysis confirmed the significant findings reported in the preceding sections. 
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 327 330 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPO</italic>
###xml 335 339 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 342 343 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b008">8</xref>
###xml 1044 1046 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b023">23</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
In CP the VHL-HIF signalling pathway is specifically and systemically impaired, uniquely facilitating human research into this transcriptional system. Previous phenotyping studies using transformed lymphocyte cell lines demonstrated increased basal expression of HIF-alpha with up-regulation of downstream target genes such as EPO and VEGF [ 8]. Using fresh lymphocytes, we have now confirmed that expression of classic HIF-regulated genes (of disparate functions) is increased under non-hypoxic conditions in CP patients. We have also shown that differences in gene expression are less distinct in hypoxia, consistent with a relative diminution in the impact of the mutant VHL when oxygen tension falls and the rate of hydroxylation of HIF-alpha slows. A retrospective matched cohort study conducted in Chuvashia found that homozygosity for the Chuvash VHL mutation was associated with vertebral haemangiomas, varicose veins, lower systemic blood pressures, and premature mortality partially related to cerebrovascular and thrombotic events [ 23]. The current study focuses on the phenotypic consequences of this mutation in systemic respiratory and cardiovascular physiology. 
###end p 54
###begin p 55
###xml 24 27 24 27 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pco</sc>
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 498 499 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 494 499 494 499 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pco <sub>2</sub></sc>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b024">24</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b025">25</xref>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b026">26</xref>
###xml 48 55 <span type="species:ncbi:9606">patient</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 1047 1052 <span type="species:ncbi:9606">human</span>
The lower air-breathing Pco2 measured in the CP patient group indicates an altered set point for respiratory control in the direction of an elevation in pulmonary ventilation (i.e., ventilation is somewhat higher than normal in relation to metabolism). This is consistent with measurements of their ventilation during isocapnic euoxia, which tended to be higher than for the controls although the difference was not statistically significant. It is striking that CP patients had both a reduced Pco 2 set point for the respiratory controller and an abnormally high acute hypoxic ventilatory sensitivity, as together these are characteristic of individuals who are acclimatised to hypoxia at high altitude [ 24, 25]. Indeed, the difference in ventilatory sensitivity to hypoxia between CP patients and controls was likely to be even greater than reported, since the relative hypocapnia of the patients would have inhibited their ventilatory response [ 26]. These results are clearly consistent with the notion that the VHL-HIF system is involved in human ventilatory acclimatisation to hypoxia, and establish an important role for VHL in regulating respiratory control in hypoxia-naive individuals. 
###end p 55
###begin p 56
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b023">23</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b027">27</xref>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b028">28</xref>
###xml 1090 1091 1090 1091 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1087 1091 1087 1091 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Po <sub>2</sub></sc>
###xml 1391 1393 1391 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b029">29</xref>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 569 577 <span type="species:ncbi:9606">patients</span>
###xml 790 797 <span type="species:ncbi:9606">patient</span>
###xml 961 969 <span type="species:ncbi:9606">patients</span>
###xml 1187 1195 <span type="species:ncbi:9606">patients</span>
###xml 1237 1244 <span type="species:ncbi:9606">patient</span>
CP patients were found to have a degree of pulmonary arterial hypertension. This most probably reflects HIF-regulated elevation in pulmonary vasomotor tone, although the increased rate of thrombotic events reported in CP [ 23] raises the theoretical possibility of chronic thromboembolic pulmonary hypertension as an alternative underlying mechanism. However, chronic thromboembolic pulmonary hypertension is rare even in patients with chronic uncontrolled myeloproliferative disease [ 27]. It is very unlikely to be present in young venesected individuals such as the patients in our study, who have no antecedent thrombotic history, hypoxaemia, or other clinical manifestations of thromboembolic disease. Furthermore, it should be noted that the presence of pulmonary hypertension in our patient group does not explain their very high pulmonary vascular sensitivity to hypoxia. A previous study measured pulmonary vasoresponsiveness to hypoxia in 26 eucapnic patients with pulmonary hypertension related to chronic obstructive lung disease [ 28]. For equivalent decrements in arterial Po 2, the increase in pulmonary arterial pressures produced by hypoxia was 4-7 times smaller in the patients with chronic lung disease than in our CP patient group. Other studies using animals have also shown that hypoxic pulmonary vasoconstriction is blunted by increased pulmonary arterial pressures [ 29]. 
###end p 56
###begin p 57
###xml 163 166 159 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 581 583 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b014">14</xref>
###xml 641 643 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b030">30</xref>
###xml 909 911 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b023">23</xref>
###xml 39 46 <span type="species:ncbi:9606">patient</span>
###xml 491 503 <span type="species:ncbi:9606">participants</span>
###xml 972 980 <span type="species:ncbi:9606">patients</span>
It is therefore remarkable that the CP patient group displayed such exquisite hypoxic pulmonary vascular sensitivity. Mild hypoxia provoked peak values for DeltaP max that correspond to systolic pulmonary arterial pressures of approximately 45 mm Hg, while the moderate hypoxic stimulus provoked extraordinary peak systolic pulmonary arterial pressures of approximately 70 mm Hg. If hypoxia were to be sustained, pulmonary arterial pressure might rise considerably higher, because in normal participants a second, gradual component of hypoxic pulmonary vasoconstriction develops [ 14] and continues to intensify for at least another 1-2 h [ 30]. Prolonged exposure to high pulmonary arterial pressures leads to right ventricular strain and eventual failure, introducing the possibility that pulmonary hypertension and exaggerated hypoxic sensitivity contribute to the premature mortality associated with CP [ 23]. This finding also raises the question of whether affected patients should avoid high altitudes and minimise long-haul air travel. 
###end p 57
###begin p 58
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b023">23</xref>
###xml 243 250 <span type="species:ncbi:9606">patient</span>
Lowered systemic blood pressure has previously been reported in CP [ 23], suggesting VHL-HIF may be involved in setting basal systemic vascular tone. Although no statistically significant differences in blood pressure were seen in our limited patient sample, our findings do implicate VHL-HIF in modulating the heart rate response to acute hypoxia. 
###end p 58
###begin p 59
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b031">31</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b032">32</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b033">33</xref>
###xml 233 238 <span type="species:ncbi:9606">human</span>
###xml 512 524 <span type="species:ncbi:9606">participants</span>
###xml 663 671 <span type="species:ncbi:9606">patients</span>
In this study, it was clear that each individual with CP was physiologically very abnormal. There is no evidence to suggest that these pronounced physiological abnormalities were confounded by polycythaemia per se. Although relevant human data are lacking, animal studies have shown that the pulmonary vascular response to acute hypoxia is independent of haematocrit [ 31], and that the hypoxic ventilatory response is either inhibited [ 32] or unchanged [ 33] acutely by polycythaemia. In any case, none of the participants was polycythaemic at the time of the study, as therapeutic venesection had normalised the haemoglobin and the haematocrit in the affected patients. 
###end p 59
###begin p 60
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b004">4</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b005">5</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 695 702 <span type="species:ncbi:9606">patient</span>
###xml 773 785 <span type="species:ncbi:9606">participants</span>
###xml 832 840 <span type="species:ncbi:9606">patients</span>
###xml 1142 1154 <span type="species:ncbi:9606">participants</span>
###xml 1218 1230 <span type="species:ncbi:9606">participants</span>
Treatment of polycythaemia with venesection renders patients iron-deficient. Iron is an obligate co-factor in the prolyl hydroxylation reaction by which HIF is regulated [ 4, 5], and iron deficiency inhibits this reaction, at least in vitro. Thus, it is possible that, through effects on HIF-regulated gene expression, iron deficiency contributed to the physiological abnormalities seen in the CP patients. Our study did not detect any significant physiological differences between the polycythaemia control group, who were clearly iron-deficient, and the normal controls. This tends to suggest that associated iron deficiency is not a factor underlying the abnormalities observed within the CP patient group. It should nevertheless be noted that the polycythaemia control participants were not as severely iron-deficient as the CP patients, and also that there was some suggestion that the ventilatory response to moderate (but not mild) hypoxia of the polycythaemia control group was intermediate between that of the normal control and CP groups. Thus, while we were unable to show that the iron deficiency present in polycythaemia control participants resulted in abnormal cardiopulmonary physiology, the number of participants studied was small and the possibility clearly remains that iron deficiency may phenocopy VHL loss of function to some limited extent. 
###end p 60
###begin p 61
###xml 291 293 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b034">34</xref>
###xml 295 297 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b035">35</xref>
###xml 420 422 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b036">36</xref>
###xml 461 463 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b037">37</xref>
###xml 33 45 <span type="species:ncbi:9606">participants</span>
###xml 85 96 <span type="species:ncbi:9606">participant</span>
One of the polycythaemia control participants was taking atenolol. Results from this participant were excluded from the analysis of systemic vascular data but were included in all other analyses. Ventilatory responses to acute hypoxia are not affected by beta-adrenergic receptor blockade [ 34, 35], and animal studies suggest that beta-receptor antagonists either have no effect on hypoxic pulmonary vasoconstriction [ 36] or enhance the phenomenon somewhat [ 37]. 
###end p 61
###begin p 62
###xml 52 64 <span type="species:ncbi:9606">participants</span>
Overall, the results from the polycythaemia control participants support the notion that the cardiopulmonary abnormalities in CP result directly from dysregulation of the VHL pathway rather than indirectly from the haematological manifestations of the disease.
###end p 62
###begin p 63
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b002">2</xref>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b008">8</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b038">38</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b041">41</xref>
###xml 562 565 558 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
The major known role of VHL is its regulation of the HIF transcriptional system [ 2]. The results from the present study and others [ 8] demonstrate that the Chuvash VHL mutation results in up-regulation of at least some HIF-responsive genes under conditions of euoxia. Furthermore, a role for the HIF system in cardiopulmonary regulation has been observed through the attenuation of cardiopulmonary responses to hypoxia in mice that are heterozygously deficient for functional HIF genes [ 38- 41]. This down-regulation of cardiopulmonary responses in HIF-alpha +/- mice is consistent with the up-regulation of cardiopulmonary responses seen in the CP patients in this study. It thus seems likely that the phenotype observed in the current study results from effects of VHL on the HIF system, though the involvement of other (as yet unknown) proteins with which VHL may interact cannot be excluded. 
###end p 63
###begin p 64
###xml 243 248 239 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#946;</sub>
###xml 166 304 166 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">endothelin-1, endothelial nitric-oxide synthase, tyrosine hydroxylase, &#945; <sub>1&#946;</sub>-adrenergic receptor, adrenomedullin, heme oxygenase-1, </italic>
###xml 309 335 302 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">atrial natriuretic peptide</italic>
###xml 338 340 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b042">42</xref>
###xml 498 500 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b043">43</xref>
###xml 637 639 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030290-b044">44</xref>
###xml 126 132 <span type="species:ncbi:9606">humans</span>
###xml 516 531 <span type="species:ncbi:10090">transgenic mice</span>
Involvement of VHL-HIF in vasomotor regulation is consistent with the nature of some of the genes HIF is known to regulate in humans and animals. These genes include endothelin-1, endothelial nitric-oxide synthase, tyrosine hydroxylase, alpha 1beta-adrenergic receptor, adrenomedullin, heme oxygenase-1,  and atrial natriuretic peptide [ 42]. Tyrosine hydroxylase has also been hypothetically linked to ventilatory control through its regulation of catecholamine biosynthesis in the carotid body [ 43]. In addition, transgenic mice over-expressing EPO in the brain were recently shown to have abnormal ventilatory responses to hypoxia [ 44], raising the further possibility that the VHL-HIF pathway influences ventilation through regulating cerebral expression of EPO. 
###end p 64
###begin p 65
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 251 256 <span type="species:ncbi:9606">human</span>
###xml 285 293 <span type="species:ncbi:9606">Patients</span>
###xml 590 596 <span type="species:ncbi:9606">humans</span>
Although the number of patients in our study was small, and as such our findings may not be completely representative of CP patients overall, our findings nevertheless demonstrate that a relatively subtle disorder of HIF degradation profoundly alters human cardiopulmonary physiology. Patients with CP had elevated basal ventilation and pulmonary vascular tone, with extremely high ventilatory, pulmonary vasoconstrictive, and heart rate responses to acute hypoxia. The abnormalities they displayed mimicked those caused by acclimatisation to hypoxia at high altitude. We conclude that, in humans, the VHL-HIF transcriptional signalling pathway, which is central to intracellular oxygen sensing, also appears to play a major role in calibrating the organ systems upon which cellular oxygen delivery ultimately depends. Further research is required to investigate the exact mechanisms involved. Our study also has implications for current HIF-related therapeutic research, much of which is directed towards pharmacological inhibition of the prolyl hydroxylases that negatively regulate HIF. Such therapies are intended to up-regulate HIF-dependent genes and promote angiogenesis in ischaemic/hypoxic vascular disease, but will now require surveillance for the undesired physiological effects of exaggerated hypoxic responses and elevated pulmonary vascular tone. Conversely, HIF inhibitors under investigation as anti-cancer treatments may have opposite physiological effects, conceivably introducing potential applications for these agents in diseases such as pulmonary hypertension.
###end p 65
###begin p 66
###xml 65 73 <span type="species:ncbi:9606">patients</span>
We thank David O'Connor for expert technical assistance, and the patients and volunteers who took part in this study.
###end p 66
###begin p 67
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Author contributions. TGS, JTB, and PAR designed the study. PHM, CWP, and PJR contributed to study design. TGS, TRL, DML, DLL, PHM, MFM, CJM, MJP, CWP, and MT identified and recruited patients to the study. TGS, GMB, CL, and NPT conducted the physiology experiments. JTB conducted the gene expression experiments. TGS, JTB, GMB, TRL, DML, DLL, PHM, MFM, CJM, CWP, PJR, NPT, MT, and PAR analysed the data and contributed to preparation of the paper. TGS, PJR, and PAR wrote the paper. 
###end p 67
###begin title 68
References
###end title 68
###begin article-title 69
Hydroxylation of HIF-1: Oxygen sensing at the molecular level
###end article-title 69
###begin article-title 70
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
###end article-title 70
###begin article-title 71
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein
###end article-title 71
###begin article-title 72
###xml 76 77 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O 2-regulated prolyl hydroxylation 
###end article-title 72
###begin article-title 73
###xml 93 94 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
HIF-alpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O 2 sensing 
###end article-title 73
###begin article-title 74
HIF at the crossroads between ischemia and carcinogenesis
###end article-title 74
###begin article-title 75
von Hippel-Lindau disease
###end article-title 75
###begin article-title 76
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
###end article-title 76
###begin article-title 77
Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry
###end article-title 77
###begin article-title 78
A new mathematical model for relative quantification in real-time RT-PCR
###end article-title 78
###begin article-title 79
A prediction-correction scheme for forcing alveolar gases along certain time courses
###end article-title 79
###begin article-title 80
###xml 72 75 <span type="species:ncbi:9606">man</span>
The properties of a turbine device for measuring respiratory volumes in man
###end article-title 80
###begin article-title 81
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation
###end article-title 81
###begin article-title 82
###xml 35 40 <span type="species:ncbi:9606">human</span>
Two temporal components within the human pulmonary vascular response to  2 h of isocapnic hypoxia
###end article-title 82
###begin article-title 83
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography
###end article-title 83
###begin article-title 84
Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: A randomized, double-blind, placebo-controlled crossover trial
###end article-title 84
###begin article-title 85
Stress doppler echocardiography for identification of susceptibility to high altitude pulmonary edema
###end article-title 85
###begin article-title 86
Estimation of pulmonary artery pressure by Doppler echocardiography in normal subjects made hypoxic
###end article-title 86
###begin article-title 87
Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude
###end article-title 87
###begin article-title 88
New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure
###end article-title 88
###begin article-title 89
Operation Everest II: Elevated high-altitude pulmonary resistance unresponsive to oxygen
###end article-title 89
###begin article-title 90
Pulmonary arterial hypertension
###end article-title 90
###begin article-title 91
Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors
###end article-title 91
###begin article-title 92
Physiological observations made on Pike's Peak, Colorado, with special reference to adaptation to low barometric pressure
###end article-title 92
###begin article-title 93
###xml 42 45 <span type="species:ncbi:9606">men</span>
Augmented hypoxic ventilatory response in men at altitude
###end article-title 93
###begin article-title 94
Hypoxic respiratory response during acute stable hypocapnia
###end article-title 94
###begin article-title 95
Unexplained pulmonary hypertension in chronic myeloproliferative disorders
###end article-title 95
###begin article-title 96
Vascular and cardiac reactivity in pulmonary hypertension due to chronic obstructive lung disease: Assessment with various oxygen concentrations
###end article-title 96
###begin article-title 97
Blunted hypoxic pulmonary vasoconstriction by increased lung vascular pressures
###end article-title 97
###begin article-title 98
###xml 19 24 <span type="species:ncbi:9606">human</span>
Time-course of the human pulmonary vascular response to 8 hours of isocapnic hypoxia
###end article-title 98
###begin article-title 99
###xml 53 57 <span type="species:ncbi:10116">rats</span>
Polycythemia and the acute hypoxic response in awake rats following chronic hypoxia
###end article-title 99
###begin article-title 100
###xml 75 79 <span type="species:ncbi:9913">calf</span>
Decreased ventilatory response to hypoxia during acute polycythemia in the calf
###end article-title 100
###begin article-title 101
###xml 56 60 <span type="species:ncbi:9615">dogs</span>
Ventilatory response to hypoxia in acutely polycythemic dogs
###end article-title 101
###begin article-title 102
###xml 86 92 <span type="species:ncbi:9606">humans</span>
Ventilatory effects of 8 hours of isocapnic hypoxia with and without beta-blockade in humans
###end article-title 102
###begin article-title 103
###xml 52 55 <span type="species:ncbi:9606">man</span>
Effects of adrenergic stimulation on ventilation in man
###end article-title 103
###begin article-title 104
###xml 71 75 <span type="species:ncbi:9615">dogs</span>
Sympathetic modulation of hypoxic pulmonary vasoconstriction in intact dogs
###end article-title 104
###begin article-title 105
###xml 79 83 <span type="species:ncbi:9615">dogs</span>
Chronic propranolol treatment decreases pulmonary artery pressure in conscious dogs
###end article-title 105
###begin article-title 106
###xml 89 93 <span type="species:ncbi:10090">mice</span>
Defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha
###end article-title 106
###begin article-title 107
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha
###end article-title 107
###begin article-title 108
Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia
###end article-title 108
###begin article-title 109
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia
###end article-title 109
###begin article-title 110
Oxygen sensing by HIF hydroxylases
###end article-title 110
###begin article-title 111
###xml 58 61 <span type="species:ncbi:10116">rat</span>
Regulation of tyrosine hydroxylase gene expression in the rat carotid body by hypoxia
###end article-title 111
###begin article-title 112
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Erythropoietin regulates hypoxic ventilation in mice by interacting with brainstem and carotid bodies
###end article-title 112
###begin title 113
Abbreviations
###end title 113
###begin p 114
maximum systolic pressure gradient across the tricuspid valve (a standard echocardiographic index of pulmonary vascular tone)
###end p 114
###begin p 115
Chuvash polycythaemia
###end p 115
###begin p 116
erythropoietin
###end p 116
###begin p 117
hypoxia-inducible factor
###end p 117
###begin p 118
end-tidal partial pressure of carbon dioxide
###end p 118
###begin p 119
end-tidal partial pressure of oxygen
###end p 119
###begin p 120
partial pressure of carbon dioxide
###end p 120
###begin p 121
partial pressure of oxygen
###end p 121
###begin p 122
vascular endothelial growth factor
###end p 122
###begin p 123
von Hippel-Lindau tumour suppressor protein
###end p 123
###begin title 124
Figures and Tables
###end title 124
###begin title 125
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Aldolase C and VEGF mRNA Expression at Different Oxygen Tensions 
###end title 125
###begin p 126
###xml 334 344 334 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aldolase C</italic>
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 584 585 582 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 603 604 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 86 98 <span type="species:ncbi:9606">participants</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
Lymphocytes were isolated from venous blood taken from CP patients and normal control participants, and incubated at eight different levels of oxygen tension prior to RNA isolation. Gene expression is shown relative to a standard calibrator sample. Basal gene expression at 20% oxygen was significantly higher in CP patients for both Aldolase C (A) and VEGF (B) ( p < 0.05). Both genes were induced by hypoxia, and at the lowest oxygen tension (0.1%) expression was no longer significantly different for either gene. Values are mean +/- standard error of the mean. Asterisks indicate p < 0.05 (unpaired t-test). 
###end p 126
###begin title 127
End-Tidal Gas Control, Ventilatory, and Pulmonary Vascular Responses to Mild and Moderate Hypoxia
###end title 127
###begin p 128
###xml 39 40 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 37 40 37 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O <sub>2</sub></sub>
###xml 33 40 33 40 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet <sub>O <sub>2</sub></sub></sc>
###xml 45 48 45 48 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 51 52 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 48 52 48 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO <sub>2</sub></sub>
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 79 82 79 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O <sub>2</sub></sub>
###xml 75 82 75 82 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet <sub>O <sub>2</sub></sub></sc>
###xml 120 123 120 123 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 126 127 126 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 123 127 123 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO <sub>2</sub></sub>
###xml 216 219 216 219 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pet</sc>
###xml 222 223 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 219 223 219 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO <sub>2</sub></sub>
###xml 148 155 <span type="species:ncbi:9606">patient</span>
(A and B) End-tidal gas control. Pet O 2 and PetCO 2 were well controlled. Pet O 2 was well matched between all groups. PetCO 2 was lower in the CP patient group, reflecting this group's lower baseline air-breathing PetCO 2. 
###end p 128
###begin p 129
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 325 326 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
(C and D) Ventilation, given at body temperature and pressure, saturated with water vapour. Mild hypoxia provoked an increase in ventilation of 4.4 l/min in the CP patients versus 1.6 l/min in normal controls ( p < 0.05), while moderate hypoxia induced increases of 24.5 versus 10.0 l/min in these two groups, respectively ( p < 0.05). 
###end p 129
###begin p 130
###xml 104 107 100 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 193 196 185 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 304 305 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 360 363 348 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 438 439 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 231 238 <span type="species:ncbi:9606">patient</span>
(E and F) Pulmonary vascular tone. This was assessed using Doppler echocardiography to determine DeltaP max, a standard non-invasive index of pulmonary vascular tone. With mild hypoxia, DeltaP max increased by 11.5 mm Hg in the CP patient group compared with only 1.1 mm Hg in the normal control group ( p < 0.05). Moderate hypoxia stimulated a rise in DeltaP max of 35.3 mm Hg compared with 6.1 mm Hg in these two groups, respectively ( p < 0.001). 
###end p 130
###begin p 131
All responses are shown during mild (A, C, and E) and moderate (B, D, and F) hypoxia. Values are mean +/- standard error of the mean.
###end p 131
###begin title 132
Systemic Vascular Responses to Mild and Moderate Hypoxia
###end title 132
###begin p 133
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 79 86 <span type="species:ncbi:9606">patient</span>
###xml 140 152 <span type="species:ncbi:9606">participants</span>
(A and B) Heart rate. Mild hypoxia provoked a rise of 11.7 beats/min in the CP patient group, compared with 3.6 beats/min in normal control participants ( p < 0.05). No other statistically significant differences in systemic vascular responses were detected between these two groups. 
###end p 133
###begin p 134
(C and D) Blood pressure, showing systolic pressure (upper plot) and diastolic pressure (lower plot).
###end p 134
###begin p 135
(E and F) Cardiac output, assessed non-invasively using Doppler echocardiography.
###end p 135
###begin p 136
All responses are shown during mild (A, C, and E) and moderate (B, D, and F) hypoxia. Values are mean +/- standard error of the mean.
###end p 136
###begin title 137
###xml 40 52 <span type="species:ncbi:9606">Participants</span>
Sensitivities to Hypoxia for Individual Participants
###end title 137
###begin p 138
###xml 101 112 <span type="species:ncbi:9606">participant</span>
###xml 178 190 <span type="species:ncbi:9606">participants</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
Results are shown in terms of the number of (normal control group) standard deviations by which each participant's response differed from the mean response of the normal control participants. The patients with CP were significantly different from the normal control group in their ventilatory and pulmonary vascular responses to both mild and moderate hypoxia, and in their heart rate responses to mild hypoxia. BP, blood pressure.
###end p 138
###begin p 139
###xml 0 11 <span type="species:ncbi:9606">Participant</span>
Participant Characteristics
###end p 139
###begin p 140
Arterial and Venous Blood Analyses
###end p 140
###begin p 141
###xml 131 136 <span type="species:ncbi:9606">human</span>
Citation: Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, et al. (2006) Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med 3(7): e290. DOI: 10.1371/journal.pmed.0030290
###end p 141
###begin p 142
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: TGS is supported by a Rhodes Scholarship. This work was funded by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 
###end p 142

